Silo Pharma, Inc.

SILO Healthcare Biotechnology

Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.18 0.02 −1.67%
Market cap
$1.9M
P/E
0.0×
Fwd P/E
18.4×
Dividend yield
—
F-score
4/9
Altman Z
−3.06
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— 3 4 4

+8 more TTM periods

ROE
(91.23%) (99.94%) (74.56%) (86.11%)
ROA
(70.96%) (74.98%) (56.30%) (67.91%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(96.21%) (79.41%) (62.75%) (93.05%)
Average Days of Receivables
— 0.00 0.00 0.00
Free Cash Flow per Share
(3.57) (4.15) (8.34) (7.71)
Free Cash Flow
(3.92) (3.80) (4.66) (4.80)
Other line items

Show all line items

Columns are period end dates